Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
A Multidose, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
This study was withdrawn before enrollment.
Location not clearly listed
A Pilot Study to Augment™ Bone Graft Plus Evaluate the Safety of Allograft for Treatment of Osteochondral Defects (OCD) of the Knee
This study has finished and is no longer accepting participants.
In HalifaxA Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of GRX-917 in Healthy Adult Subjects
This study has finished and is no longer accepting participants.
In MelbourneThis study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In BulgariaA Phase 1b, In-Patient Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden Grove
A study to evaluate the viability and efficacy of integrating the BeyondNow suicide prevention smartphone app into a telephone support service for callers who are experiencing suicidal thoughts.
This study ended early.
In Australia
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
Read the official source — NCT00294008Electronic Schizophrenia Treatment Adherence Registry(e-STAR): An Observational, International Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres
This study has finished and is no longer accepting participants.
Location not clearly listedA RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SPONSOR OPEN, PHASE 1B STUDY TO EXAMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-06412562 IN PSYCHIATRICALLY STABLE SUBJECTS WITH SCHIZOPHRENIA
This study has finished and is no longer accepting participants.
Multiple locations, including ArcadiaA Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
This study has finished and is no longer accepting participants.
Multiple locations, including New HavenA Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
Read the official source — NCT00402584A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedA Double Blind, Randomized, Placebo Controlled, Cross-over Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
This study has finished and is no longer accepting participants.
In CambridgeProspective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors
This study has finished and is no longer accepting participants.
Multiple locations, including Bucheon-Si Gyeonggi-DoWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.